Case Report

Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) caused by a VDR mutation: A novel mechanism of dominant inheritance

Tsuyoshi Isojima, Michiyasu Ishizawa, Kazuko Yoshimura, Mayuko Tamura, Shinichi Hirose, Makoto Makishima, Sachiko Kitanaka

© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
(i.e., the parents of sufferers) show no symptoms and have normal bone development (Malloy et al., 2004, 2011). Recently, a single family has been reported to demonstrate dominant inheritance caused by a VDR mutation with a dominant-negative effect (Malloy et al., 2011). Here, we report a family with HVDRR showing dominant inheritance, in which we identified a novel mutation with a dominant-negative effect and enhanced corepressor interaction. This is the first report of a dominant-negative VDR mutation demonstrating a constitutive corepressor interaction, a mechanism similar to that in dominantly inherited thyroid hormone receptor (TR) mutations (Safer et al., 1998; Liu et al., 1998; Fozzatti et al., 2011, 2013; Bochukova et al., 2012).

2. Subjects and methods

2.1. Patient clinical observation

An 18-month-old Japanese boy was referred to our institute and evaluated for short stature and bowlegs. His body length and weight were 80.2 cm [−2.0 standard deviations (SD)] and 8.6 kg (−1.6 SD), respectively. He is the first child of nonconsanguineous parents, and his birth history was unremarkable. He started walking at the age of 14 months, but his parents felt he had a slight waddling gait. Intellectual development was within normal limits. His father had been treated for a short period with some vitamin D for rickets during childhood, which was considered to be due to simple vitamin D deficiency; his height was 173 cm, and he had a slight bowing of his legs. The patient’s paternal grandfather also had bowlegs without alopecia, although he had never been treated.

Radiographic study of the hands and knees was consistent with rickets (Fig. 1A). Blood biochemistry showed normal serum calcium (Ca) (2.2 mmol/l; reference range, 2.1–2.4) and 25(OH)D levels (20 ng/ml; insufficiency, <20). However, they showed slightly decreased serum phosphorus (P) (1.1 mmol/l; reference range, 1.3–2.0) and elevated serum alkaline phosphatase (ALP) (3346 U/l; reference range, 10–65), and 1,25(OH)2D levels (304 pg/ml; reference range, 20–70). On the basis of these findings of obvious rickets, with elevated 1,25(OH)2D, ALP, and iPTH levels and a normal 25(OH)D level, we diagnosed him with HVDRR. However, we could not exclude the possibility of vitamin D deficiency. He was effectively treated with 2 μg alfalcaldol daily without any calcium supplements, and his rickets, ALP, iPTH levels improved. The dose was tapered and stopped at the age of 4 years. At the last follow-up (age,

---

**Fig. 1.** Radiograph of the patient, a chromatogram of the novel mutation, and the family tree. (A) Radiograph of the patient at diagnosis. It showed cupping, fraying and flaring indicating that the patient had evident rickets. (B) The novel p.Q400LfsX7 mutation. In the chromatogram: nucleotides in bold black letters with underline indicate an 8-base pair deletion; and the lower part shows the subcloned normal and mutant sequences. (C) The pedigree analysis in this study.
5 years and 11 months), he had neither rickets nor alopecia and measured 106.8 cm (−1.3 SD) in height. His blood biochemistry showed normal Ca (2.4 mmol/l), P (1.5 mmol/l), ALP (622 U/l), and iPTH (53 pg/ml), but elevated 1.25(OH)2D (271 pg/ml) levels.

2.2. VDR gene analysis

We obtained informed consent for DNA analysis from the parents, and the Ethics Committee of The University of Tokyo approved the study. Genomic DNA was extracted from peripheral white blood cells using a QIAamp DNA Blood Midi Kit (Qiagen, Hilden, Germany). The entire coding region and exon–intron boundaries of the VDR gene were amplified from genomic DNA by polymerase chain reaction (PCR) using the designed PCR primers. The details of the primers and the PCR conditions will be provided on request. Subsequently, PCR products were sequenced using an ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems, Foster City, CA) and the forward and reverse primers from the PCR amplification. Direct sequencing in both directions was performed on an autosequencer (ABI PRISM 310, Genetic Analyzer; Applied Biosystems). Detected mutations were confirmed by cloning the PCR products into the pCR 2.1 vector using a TOPO TA Cloning kit (Invitrogen, Carlsbad, CA, U.S.A.). The clones derived from both alleles were sequenced.

2.3. Construction of plasmids

Expression plasmids for wild-type full-length human VDR or RXRα and a reporter plasmid for human 24-hydroxylase promoter (−367 to 0) in pGL3 were provided by S. Kato. The expression plasmids hVDR-pCMX, hVDR-flag-pCMX, hVDR-VP16-pCMX, RXRα–GAL4-pCMX, GRP1–GAL4-pCMX, and NCoR-GAL4-pCMX have been reported previously (Inaba et al., 2007). GAL4-responsive MH100(UAS)x4-tk-LUC and VDR-responsive Sppx3-tk-LUC were also used in the luciferase reporter assay (Nakano et al., 2005; Igarashi et al., 2007). The mutant plasmids (Q400LfsX7 and R370H) were created with a Quick Change Site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer’s protocol (Sato et al., 2005). VDR mutant constructs were sequence-verified to have no extra mutations.

2.4. Transcriptional activity

COS-1 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 100 unit/ml penicillin, and 100 μg/ml streptomycin at 37 °C in a humidified atmosphere containing 5% CO2. Transfections in COS-1 cells were performed by modification of previously reported methods (Sato et al., 2005; Jurutka et al., 2000). Cells that were cultured in 24-well plates were transfected with 800 ng DNA, including 300 ng 24-hydroxylase-pGL3 promoter luciferase, the indicated amounts of each human VDR expression plasmids, and 1 ng pRL-CMV (Promega, Madison, WI) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Four hours after transfection, the indicated amounts of ligand were added. After 24 h, transcriptional activity was assayed using a Dual-Luciferase Reporter Assay System (Promega). The luciferase activities of human 24-hydroxylase promoter luciferase plasmid were normalized to the luciferase activities of pRL-CMV. Transient transfections were performed in triplicate, and each experiment was repeated at least three times.

2.5. Mammalian two-hybrid analyses

Human embryonic kidney (HEK) 293 cells were cultured in DMEM containing 5% fetal bovine serum and an antibiotic–antimycotic (Nacalai, Kyoto) at 37 °C in a humidified atmosphere containing 5% CO2. Transfections in HEK293 cells were performed by the calcium phosphate coprecipitation analysis as described previously (Adachi et al., 2005). Cells that were cultured in 96-well plates were transfected with 50 ng GAL4-responsive MH100(UAS)x4-tk-LUC reporter plasmid or VDR-responsive Sppx3-tk-LUC, 20 ng β-galactosidase-pCMX, 15 ng of each VDR, and/or the cofactor expression plasmid and pGEM carrier DNA for a total 150 ng DNA. Eight hours after transfection, the indicated amounts of ligands were added. Cells were harvested approximately 16–24 h after treatment, and luciferase and β-galactosidase activities were assayed using a luminometer and a microplate reader (Molecular Devices, Sunnyvale, CA). Luciferase data were normalized to an internal β-galactosidase control and were represented as the mean (±SD) of triplicate assays.

2.6. Competitive ligand-binding assay

LBDs of human VDR and its mutants were cloned into the GST-fusion vector pGEX-4T1 (Amersham Pharmacia Biotech, Piscataway, NJ). GST–VDR fusion proteins were expressed in BL21 DE3 cells (Promega) and purified with glutathione sepharose beads (Amersham Pharmacia Biotech). A competitive ligand-binding assay was performed by modification of previously reported methods (Nakajima et al., 1994; Solomon et al., 2001). Briefly, 500 ng GST fusion proteins were bound to glutathione sepharose and incubated with [26,27-methyl-3H]1α,25(OH)2D3 (Amersham Pharmacia Biotech) in the presence or absence of the non-radioactive ligand in a buffer (10 mM Tris–HCl, pH 7.6; 1 mM EDTA; 300 mM KC1; 1 mM dithiothreitol; 10% glycerol) for 3 h at 4 °C. After washing twice, the protein and bound 1α,25(OH)2D3 were resuspended in 200 μl of the binding buffer, and a 150 μl sample was assessed by liquid scintillation counting.

3. Results

3.1. Mutation analysis of the VDR gene

The genomic analyses for the VDR gene revealed that the patient had a novel deletion mutation and a reported variant (rs202139940). The mutation is an 8-base pair deletion in exon 10 of the VDR gene, c.1199–1206del, p.Q400LfsX7, which is predicted to result in a frameshift from codon 400 and premature termination just before helix H12 (Fig. 1B). This detected mutation was heterozygous in his father. The variant (rs202139940) is a G>A transition in exon 10 of the VDR gene, which is predicted to result in a substitution of arginine to histidine in codon 370 (R370H). This variant was also found to be heterozygous in his healthy mother. Both the patient and his mother were heterozygous for the Foki polymorphism (F/F) that alters the translational site from M1 to M4 (Jurutka et al., 2000; Haussler et al., 1998), while his father was homozygous for the f/M1 alleles.

3.2. Transcriptional activity of Q400LfsX7-VDR and R370H-VDR

To examine whether the detected Q400LfsX7 mutation and the R370H variant can affect VDR transactivation, wild-type Q400LfsX7-VDR and R370H-VDR were transiently overexpressed in COS-1 cells, and transcriptional activity was analyzed using the reporter 24-hydroxylase promoter. R370H-VDR showed negligible transcriptional activity. Similar results were also observed in HEK293 cells (data not shown). These results indicated that the Q400LfsX7-VDR mutant had completely lost all transcriptional activity, whereas R370H remained normal.

3.3. The dominant-negative effect of Q400LfsX7-VDR on wild-type VDR

We hypothesize that the heterozygous Q400LfsX7 mutation was the molecular cause of his HVDRR. We examined the dominant-negative effect of Q400LfsX7-VDR on the wild-type product by increasing the mutant-to-wild-type protein ratio with 5 nM of 1,25(OH)2D3. When equal amounts of wild-type VDR and Q400LfsX7-VDR proteins were
the presence or absence of 400-fold excess nonradioactive 1,25(OH)2D3. GST control proteins incubated with increasing concentrations of [3H]1,25(OH)2D3 in 1,25(OH)2D3, and dspeci
VDR proteins in the presence or absence of excess unlabeled [3H]1,25(OH)2D3 effectively bound to wild-type VDR and R370H-VDR but did not bind to Q400LfsX7-VDR. This result indicated that ligand binding affinity of Q400LfsX7-VDR was completely impaired (Fig. 2C).

3.5. Interaction with RXR, coactivator, and corepressor of Q400LfsX7-VDR and R370H-VDR

Interactions between VDR mutants, RXR, the coactivator, or the corepressor were analyzed by a mammalian two-hybrid assay using hVDR-VP16-pCMX, RXRx-GAL4-pCMX, GRIP1-GAL4-pCMX, and NCoR-GAL4-pCMX, respectively. HEK293 cells were cotransfected with hVDR-VP16-pCMX, the MH100(UAS)x4-tk-LUC reporter, and RXRx-GAL4-pCMX and were treated with increasing concentrations of 1,25(OH)2D3. R370H-VDR interacted with RXRx, similar to wild-type-VDR, in a dose-dependent manner of the ligand. However, Q400LfsX7-VDR did not interact with RXRx (Fig. 3A). This finding suggested that Q400LfsX-VDR had impaired heterodimerization with RXR. Next, we analyzed the interaction with a coactivator, GRIP1 (Fig. 3B). 1,25(OH)2D3 induced concentration-dependent associations of GRIP1 with wild-type or R370H-VDR. On the other hand, the association of Q400LfsX7-VDR with GRIP1 was not identified in any amounts of 1,25(OH)2D3 (Fig. 3B). Then, the interaction of VDR with a corepressor, NCoR, was evaluated with similar experiments (Fig. 3C). Wild-type or R370H-VDR showed an interaction with NCoR in the absence of the ligand, which decreased by adding 1,25(OH)2D3. In contrast, Q400LfsX7-VDR had a strong interaction with NCoR, which did not decrease by adding 1,25(OH)2D3 (Fig. 3C). These data indicated that Q400LfsX7 displayed a defective release of NCoR in response to the ligand.

3.6. VDRE interactions with Q400LfsX7-VDR or R370H-VDR

We next assessed the interaction of the VDR mutants and VDRE by transfecting VP16-VDR chimeric receptors together with the VDRE reporter. Because of ligand-independent activity, the luciferase activities of VP16 chimeric receptors showed an interaction between the receptor and the binding element (Makishima et al., 2002; Adachi et al., 2004; Endo-Umeda et al., 2012). HEK293 cells were transfected with VP16-VDR chimeric mutants together with the luciferase reporter containing a VDR-responsive inverted repeat-6 element from the CYP3A4 promoter (Makishima et al., 2002). The activity was compared with the activity of those without VP16 to differentiate from transcriptional activity. Wild-type VP16-VDR or VP16-R370H-VDR induced luciferase activities in the absence of the ligand, and adding the ligand increased the activity (compare Fig. 3D lanes 5–12 with Fig. 3E lanes 5–12). This result suggested that these VDRs interacted with VDRE without the ligand and had ligand-dependent enhancement. In contrast, VP16-Q400LfsX7-VDR had ligand-independent activity (compare Fig. 3D lanes 13–16 with Fig. 3E lanes 13–16). Thus, Q400LfsX7-VDR could interact with VDRE, although the interaction was not influenced by the ligand (Fig. 3D lanes 13–16).

4. Discussion

We have identified and presented a novel VDR mutation (Q400LfsX7) with a dominant negative effect on wild-type-VDR in a family with dominantly inherited HVDRR. Because HVDRR is usually transmitted autosomal recessively, and because our patient had the R370H variant, we initially believed that the mutation and the variant were the molecular basis for his HVDRR. However, when we assessed the functionality of R370H using the Sorting Intolerant from Tolerant (SIFT) web-based tool (http://sift.jcvi.org) and the Polymorphism Phenotyping 2 (PolyPhen2) tool (http://genetics.bwh.harvard.edu/pph2) by homology modeling and threading, R370H was described as “tolerated” and “benign,” respectively. Furthermore, considering that rickets was dominantly inherited in this family (Fig. 1C), and that the patient showed a clinical course similar to that shown by his father, who had expressed, transcriptional activity was reduced by approximately 50%, and the increasing amounts of the mutant VDR further repressed wild-type VDR transcriptional activity (Fig. 2B). This finding demonstrated that Q400LfsX7-VDR had a dominant-negative effect on wild-type VDR. However, R370H-VDR did not affect wild-type VDR transcriptional activity (Fig. 2B). Moreover, Q400LfsX7-VDR showed a dominant-negative effect on R370H-VDR activity, similar to its effect on wild-type-VDR (data not shown). Similar results were observed in HEK293 cells using VDR-responsive Sppx3-tk-LUC (data not shown).

3.4. Ligand binding ability of Q400LfsX7-VDR and R370H-VDR

The binding affinity of 1,25(OH)2D3 of Q400LfsX7 or R370H-VDR was examined by the competitive binding assay. Isotopically labeled 1,25(OH)2D3 was incubated with glutathione-S-transferase (GST)–VDR proteins in the presence or absence of excess unlabeled 1,25(OH)2D3, and specific binding of 1,25(OH)2D3 was calculated. [3H]1,25(OH)2D3 effectively bound to wild-type-VDR and R370H-VDR but did not bind to Q400LfsX7-VDR. This result indicated that
an identical heterozygous Q400LfsX7 mutation, we hypothesized that this mutation was the more likely molecular cause of his HVDRR. Indeed, the function of R370H-VDR was almost identical to wild-type VDR, including its transcriptional activity, ligand binding, and interactions with RXR, cofactors, and VDRE (Figs. 2-3). Conversely, transcriptional activity and ligand binding ability of Q400LfsX7-VDR were completely impaired (Fig. 2A and C). More importantly, the mutant had a dominant-negative effect on wild-type-VDR (Fig. 2B). Thus, we concluded that the heterozygous Q400LfsX7 mutation caused the dominantly inherited HVDRR in this family through its dominant-negative effect on wild-type-VDR.

To our knowledge, this is the second reported pedigree of dominantly inherited HVDRR. The mutation detected in the first reported family (E420A) has been reported to show a dominant-negative effect (Malloy et al., 2011). In this study, we found that our Q400LfsX7 mutant differed from that in the previous report in terms of several functional properties. First, ligand binding was completely abolished in Q400LfsX7 (Fig. 2C), but remained in the E420A mutant. Second, Q400LfsX7 did not interact with RXR (Fig. 3A), while E420A could bind with RXR (Malloy et al., 2011). Third and importantly, our mutant strongly interacted with NCoR (Fig. 3C). Fourth, we demonstrated that Q400LfsX7 could interact with VDRE (Fig. 3D). These findings suggested that the dominant-negative effect of Q400LfsX7 was caused by a constitutive interaction with NCoR that may interact with VDRE to inhibit the activity of liganded wild-type-VDR. It is interesting that a similar molecular mechanism was postulated in the syndrome of resistance to thyroid hormone (RTH) caused by mutations in the TR α and β genes (THRA and THRβ, respectively) (Safer et al., 1998; Liu et al., 1998; Fozzatti et al., 2011, 2013; Bochukova et al., 2012). In contrast to HVDRR, RTH is usually an autosomal dominant disease. This dominant inheritance had been attributed to the dominant-negative effect of mutant THRA or THRβ by failing to dissociate with NCoR (Safer et al., 1998; Fozzatti et al., 2011; Bochukova et al., 2012, Refetoff et al., 1993; Jameson, 1994). Most interestingly, the THRA E403X mutant lacks helix H12 and has similarly enhanced copressor interaction and absent ligand binding through its loss of amino acids critical for hormone binding and coactivator recruitment, as shown by crystallographic modeling (Bochukova et al., 2012). We speculated that Q400LfsX7-VDR also caused an inability to release a coressor by exposing a hydrophobic cleft on the receptor surface through the loss of helix H12. These findings suggested that HVDRR may be inherited as a dominant trait if the mutant has a constitutive coressor interaction causing a dominant-negative effect, similar to RTH defects.

It is notable that our patient did not have alopecia. Cumulative data indicate that functional VDR is required for hair growth, and that alopecia is unrelated to the calcium or metabolic abnormalities that cause
rickets [Malloy and Feldman, 2011]. In addition, previous data indicate that VDR mutations cause defects in DNA binding, and that RXR heterodimerization or the absence of VDR causes alopecia, and mutations that alter VDR affinity for 1,25(OH)2D3 or disrupt coactivator interactions do not cause alopecia (Malloy and Feldman, 2011). Our finding suggested that, although Q400fsX7-VDR did not interact with RXR, the mutant did not affect its dominant-negative effect on wild-type VDR for the regulation of the hair cycle. A possible explanation is that Q400fsX7-VDR may not be overexpressed compared with wild-type VDR in the hair follicle. Further research using this mutant is necessary to elucidate the role of VDR in hair growth and differentiation.

Our results suggested that some patients with vitamin D-deficient rickets may have a VDR mutation. Our patient had obvious rickets and short stature but did not have hypocalcemia. His symptoms were relatively mild when compared with the classic clinical pattern of HVDRR, and his clinical course that the medication could be stopped by 4 years of age was similar to that of vitamin D-deficient rickets. In fact, his father was treated with vitamin D under the misdiagnosis of vitamin D-deficient rickets. In addition, aside from bowlegs, his unexamined paternal grandfather was otherwise asymptomatic without medication. The resolution of vitamin D resistance in patients with HVDRR has been previously described, but it typically occurs around puberty [Tiosano et al., 2011]. We consider that mild cases of HVDRR may be misdiagnosed as vitamin D deficiency or remain undiagnosed. Our results expand the concept of HVDRR and enrich our understanding of VDR function in the pathogenesis of HVDRR.

5. Conclusion

We identified a novel VDR mutation (Q400fsX7) with a dominant-negative effect on wild-type VDR in a family with dominantly inherited HVDRR, and we clarified that the mutant interacted strongly with NCOR. These findings suggested a distinct inheritance of HVDRR that expanded our understanding of the condition. Further investigations and pedigree analyses are needed to reveal the mechanism underlying dominantly inherited HVDRR.

Disclosure statement

The authors declare no conflicts of interest.

Acknowledgments

We are grateful to Dr S. Kato for providing the plasmids, and Minako Takaki and Reiko Onai for their technical support. This study was supported by Grant-in-Aid from the Ministry of Education, Science, Sports, and Culture of Japan (23591489).

References

Adachi, R., Shulman, A.I., Yamamoto, K., Shimomura, I., Yamada, S., Mangelbos, D.J., Makishima, M., 2004. Structural determinants for vitamin D receptor response to endocrine and xenobiotic signals. Mol. Endocrinol. 18, 43–52.
Adachi, R., Honna, Y., Masuno, H., Kawanaka, K., Shimomura, I., Yamada, S., Makishima, M., 2005. Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J. Lipid Res. 46, 46–57.
Bochukova, E., Schoenmakers, N., Agostini, M., Schoenmakers, E., Rajanayagyam, O., Keogh, J.M., Henning, E., Reinemund, J., Gevers, E., Sarri, M., Downes, K., Offiah, A., Albanese, A., Halsall, D., Schwabe, J.W., Bain, M., Lindley, K., Manenti, F., Varga-Khadem, F., Khadem, F.V., Dattani, M., Farooqi, I.S., Chatterjee, K., Al-Ashwal, A., Haussler, M.R., Cheng, S.Y., 2011. Resistance to thyroid hormone is modulated by a receptor auxiliary factor required for high affinity binding to the vitamin D receptor. J. Biol. Chem. 286, 30175–30182.
Sato, U., Kitakata, S., Sekine, T., Takahashi, S., Ashida, A., Igarashi, T., 2005. Functional characterization of MLXI mutations associated with nail–patella syndrome. Pediatr. Res. 57, 783–788.
Soleman, C., Maccio, M., Gao, X.L., White, J.H., Kremer, R., 2001. The unique trypsinogen substrate of the vitamin D receptor is critical for ligand binding and transcriptional activation. J. Bone Miner. Res. 16, 39–45.
Tiosano, D., Hadad, S., Chen, Z., Nemirovsky, A., Gepstein, V., Militianu, D., Weisman, Y., Abrams, A., 2011. Calcium absorption, kinetics, bone density, and bone structure in patients with hereditary vitamin D-resistant rickets. J. Clin. Endocrinol. Metab. 96, 3701–3709.